Jeffrey Rathmell, PhD

Jeffrey Rathmell, PhD, of Vanderbilt University

Articles by Jeffrey Rathmell, PhD

ACSS2 Inhibition as a Therapeutic Strategy in ccRCC: Impacts on HIF-2α, Metabolism, and Tumor Growth

Jeffrey Rathmell, PhDRenal Cell Carcinoma Diagnostics | October 15, 2024

The group discusses how blocking ACSS2 may affect immune cells in the tumor microenvironment.

Targeting ACSS2 to Regulate HIF-2α Stability and Suppress ccRCC Growth

Jeffrey Rathmell, PhDRenal Cell Carcinoma Diagnostics | October 15, 2024

Drs. Beckermann, Rathmell, and Bacigalupa highlight the potential of ACSS2 as a therapeutic target in kidney cancer.